A Michigan woman filed a lawsuit against Merck & Co. alleging its type-2 diabetes drug Januvia caused her to develop pancreatitis.
Plaintiff Elizabeth A. Mathe was first prescribed Januvia in 2004, according to her Januvia complications lawsuit. Pancreatitis is an inflammation inside the pancreas that can have numerous causes. While the condition is treatable, it can be a precursor to pancreatic cancer, one of the most aggressive forms of the disease.
Mathe discovered she had pancreatitis in 2012, her last year of using Januvia, after she started experiencing unexplained symptoms. She was officially diagnosed with the condition on Dec. 1, 2012, and filed her type-2 diabetes drug lawsuit after she learned that Januvia was closely associated with pancreatitis and pancreatic cancer.
Mathe’s lawyers claim that she was not aware that this drug could cause such complications until recently, and had not been given proper disclosure at the time she was prescribed the medication. Therefore, Mathe was unable to make a reasonable decision at the time and is holding Merck accountable for failing to list all side effects of Januvia, her Januvia lawsuit said.
Mathe’s Januvia lawsuit accuses Merck & Co. of negligence, false advertising, concealing information, and misrepresenting a product.
The Januvia Lawsuit is Elizabeth A. Mathe v. Merck & Co., Case No. 4:14-cv-02062, in the U.S. District Court for the Southern District of Texas, Houston Division.
Overview of Januvia Complications
Januvia is one of the best-selling type-2 diabetic treatment options in the United States. Despite the financial success for Merck, as well as the medical benefits for patients and doctors, concerns have recently come up regarding some possible side effects of Januvia. Numerous adverse injury reports indicate that the drug may be causing patients to develop pancreatitis and pancreatic cancer.
While this association has yet to be proven, medical experts hypothesize that these conditions could result due to how the patients metabolizes the drug. Januvia is a dipeptidyl peptidase-4 (DPP-4) inhibitor. This and other drugs in this family work by encouraging the body’s incretin manufacturing process, which helps maintain a healthy level of insulin. Ultimately, this prevents diabetic attacks, and allows the patient to maintain a healthy level of blood-sugar.
In general, Januvia pancreatic cancer lawsuits are filed individually by each plaintiff and are not class actions.
Do YOU have a legal claim? Fill out the form on this page now for a free, immediate, and confidential case evaluation. The attorneys who work with Top Class Actions will contact you if you qualify to let you know if an individual lawsuit or class action lawsuit is best for you. Hurry — statutes of limitations may apply.
ATTORNEY ADVERTISING
Top Class Actions is a Proud Member of the American Bar Association
LEGAL INFORMATION IS NOT LEGAL ADVICE
Top Class Actions Legal Statement
©2008 – 2026 Top Class Actions® LLC
Various Trademarks held by their respective owners
This website is not intended for viewing or usage by European Union citizens.
Get Help – It’s Free
Join a Free Januvia, Janumet, Byetta, Victoza Cancer Class Action Lawsuit Investigation
If you or your loved one took Januvia, Victoza, Janumet or Byetta and were diagnosed with pancreatic cancer or thyroid cancer, you have a legal claim. See if you qualify by filling out the short form below.
An attorney will contact you if you qualify to discuss the details of your potential case at no charge to you.
Oops! We could not locate your form.
